GlassScriptPhysician profile
Jane Y Bang
NPI 1588740955
$11,162.62
in general payments reported to CMS, 2019-2025
38 companies · $664 in 2025
The $664 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,000 · 2020: $915 · 2021: $2,474 · 2022: $1,975 · 2023: $1,497 · 2024: $1,638 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,798.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,948.12 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $1,479.67 | 2019-2025 | |
| Lilly USA, LLC | $1,175.25 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $782.62 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $727.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $583.51 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $451.55 | 2019-2025 | Repatha, Prolia, Evenity |
| E.R. Squibb & Sons, L.L.C. | $411.49 | 2019-2023 | Eliquis |
| Gilead Sciences, INC. | $411.08 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $361.56 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $354.14 | 2019-2024 | Xarelto |
| Abbvie INC. | $336.42 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Merck Sharp & Dohme LLC | $330.31 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.81 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $328.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Bang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.